Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFC14A
Source: 0000930413-25-001273
Chunk: 58

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFC14A
Chunk 58
---
 our Board on a phased basis, the Declassification
Restatement will also implement other changes to conform certain cross-references to the Company’s Amended and Restated Bylaws,
as they were amended and restated subsequent to the date of the Company’s original certificate of incorporation.

Effective Date of Declassification Restatement

If stockholders approve and adopt the Declassification Restatement,
it will become effective upon the filing of the proposed amendment and restatement of our Restated Certificate of Incorporation with the
Secretary of State of the State of Delaware, which the Company intends to file promptly after the requisite vote for this Proposal 4 is
obtained at the Annual Meeting. The Board will also make conforming changes to the Company’s Amended and Restated Bylaws immediately
following the effectiveness of the Declassification Restatement.

Impact if the Declassification Restatement is Not Adopted

If our stockholders do not approve this Proposal 4, we will continue
to have a classified Board, with directors serving staggered, three-year terms.

Vote Required

Approval of this proposal requires the affirmative vote of the holders
of sixty-six and two-thirds percent (66-2/3%) of the shares of common stock issued and outstanding as of the Record Date. Abstentions
and broker non-votes have the same effect as negative votes.

<div align='center'>THE BOARD OF DIRECTORS RECOMMENDS
A VOTE “FOR” PROPOSAL 4.</div>

| 42 |

<div align='center'>EXECUTIVE OFFICERS</div>

The following table sets forth certain information with respect to
our executive officers as of April 14, 2025:

| Name                 |     | Age | Position                                                                                              |
| Ryan Spencer(1)(2)   |     |  47 | Chief Executive Officer and Director(2)                                                               |
| Kelly MacDonald(2)   |     |  41 | Senior Vice President, Chief Financial Officer(2)                                                     |
| David F. Novack      |     |  63 | President and Chief Operating Officer                                                                 |
| John L. Slebir       |     |  59 | Senior Vice President, General Counsel                                                                |
| Robert Janssen, M.D. |     |  71 | Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs |

| (1) | Please see “Proposal 1 – Election of Directors” in this proxy statement for more information